Research · PMID 38740993 · Landmark study
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Nature medicine · July 2024 · Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, et al.
What this study found
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).
Why this trial matters
SELECT long-term weight analysis
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Supporting literature
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open evidence analysis